DE69233051T2 - Antikörper gegen CD40-L - Google Patents

Antikörper gegen CD40-L Download PDF

Info

Publication number
DE69233051T2
DE69233051T2 DE69233051T DE69233051T DE69233051T2 DE 69233051 T2 DE69233051 T2 DE 69233051T2 DE 69233051 T DE69233051 T DE 69233051T DE 69233051 T DE69233051 T DE 69233051T DE 69233051 T2 DE69233051 T2 DE 69233051T2
Authority
DE
Germany
Prior art keywords
cells
sequence
human
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69233051T
Other languages
German (de)
English (en)
Other versions
DE69233051D1 (de
Inventor
Richard J. Armitage
William C. Fanslow
Melanie K. Spriggs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233051(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE69233051D1 publication Critical patent/DE69233051D1/de
Application granted granted Critical
Publication of DE69233051T2 publication Critical patent/DE69233051T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69233051T 1991-10-25 1992-10-23 Antikörper gegen CD40-L Revoked DE69233051T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US783707 1991-10-25
US80572391A 1991-12-05 1991-12-05
US805723 1991-12-05

Publications (2)

Publication Number Publication Date
DE69233051D1 DE69233051D1 (de) 2003-06-12
DE69233051T2 true DE69233051T2 (de) 2004-03-11

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69233402T Expired - Fee Related DE69233402T3 (de) 1991-10-25 1992-10-23 Neue cytokine
DE69233051T Revoked DE69233051T2 (de) 1991-10-25 1992-10-23 Antikörper gegen CD40-L

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69233402T Expired - Fee Related DE69233402T3 (de) 1991-10-25 1992-10-23 Neue cytokine

Country Status (12)

Country Link
EP (2) EP0667901B2 (OSRAM)
JP (2) JP3308534B2 (OSRAM)
KR (1) KR100283541B1 (OSRAM)
AT (2) ATE239790T1 (OSRAM)
AU (1) AU661360B2 (OSRAM)
CA (2) CA2121798C (OSRAM)
DE (2) DE69233402T3 (OSRAM)
DK (3) DK0667901T4 (OSRAM)
ES (2) ES2198025T3 (OSRAM)
FI (2) FI116850B (OSRAM)
NO (2) NO317625B1 (OSRAM)
WO (1) WO1993008207A1 (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
AU677995B2 (en) * 1993-01-22 1997-05-15 Immunex Corporation Detection and treatment of mutations in a CD40 ligand gene
US5560908A (en) * 1993-01-22 1996-10-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
NZ273221A (en) * 1993-09-02 2001-09-28 Dartmouth College Pharmaceutical for inducing antigen-specific T cell tolerance
ATE179616T1 (de) * 1993-09-02 1999-05-15 Dartmouth College Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
AU680102B2 (en) * 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
ATE220331T1 (de) * 1995-03-01 2002-07-15 Immunex Corp Cd40 bindendes protein zur stimulierung der immunantwort
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
IL122174A (en) * 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
EP0833847B1 (en) * 1995-06-22 2003-09-24 Biogen, Inc. Crystals of fragments of cd40 ligand and their use
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997047390A1 (en) * 1996-06-14 1997-12-18 University Of Washington Absorption-enhanced differential extraction device
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE951551T1 (de) * 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
EP2009025B1 (en) 1998-05-14 2011-07-27 Immunex Corporation Method of inhibiting osteoclast activity
WO2000024770A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
JP2003508016A (ja) * 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
PL232477B1 (pl) 2001-09-20 2019-06-28 Immunex Corp System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
WO2004074439A2 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
JP5102028B2 (ja) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｃｄ１５４抗体
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
TWI382843B (zh) 2004-10-07 2013-01-21 Argos Therapeutics Inc 成熟樹突細胞組合物及培養彼等之方法
CA2584211C (en) 2004-10-22 2014-07-08 Amgen Inc. Methods for refolding of recombinant antibodies
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
JP5963341B2 (ja) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
CA2704457A1 (en) 2007-10-30 2009-05-07 Walter Bottje Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
HUE035508T2 (en) 2009-11-17 2018-05-02 Squibb & Sons Llc Methods for enhanced protein production
WO2011091255A1 (en) 2010-01-21 2011-07-28 The Board Of Trustees Of The University Of Arkansas Vaccine vectors and methods of enhancing immune responses
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
ES2758759T3 (es) 2013-02-14 2020-05-06 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a eimeria o limitar la infección por eimeria
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10669343B2 (en) 2015-08-05 2020-06-02 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
JP7467027B2 (ja) 2016-05-03 2024-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法
KR102323519B1 (ko) 2016-05-11 2021-11-09 암젠 인크 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택
US11267856B2 (en) * 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
IL313003A (en) 2017-02-27 2024-07-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
CA2312667A1 (en) 1993-04-29
DE69233402D1 (de) 2004-09-23
DE69233051D1 (de) 2003-06-12
NO980030D0 (no) 1998-01-05
EP0667901B1 (en) 2004-08-18
EP0897983A3 (en) 1999-03-17
AU661360B2 (en) 1995-07-20
NO941422D0 (no) 1994-04-19
DE69233402T2 (de) 2005-09-15
FI941837L (fi) 1994-05-30
FI116850B (fi) 2006-03-15
NO317625B1 (no) 2004-11-29
FI981765A0 (fi) 1998-08-17
ES2227513T5 (es) 2009-04-01
DE69233402T3 (de) 2009-06-25
AU3122693A (en) 1993-05-21
CA2121798C (en) 2007-07-24
CA2121798A1 (en) 1993-04-29
ES2198025T3 (es) 2004-01-16
NO941422L (OSRAM) 1994-06-27
DK0897983T3 (da) 2003-08-11
JPH07504083A (ja) 1995-05-11
HK1019343A1 (en) 2000-02-03
EP0897983A2 (en) 1999-02-24
NO320073B1 (no) 2005-10-17
EP0897983B1 (en) 2003-05-07
KR100283541B1 (ko) 2001-03-02
DK0822199T3 (da) 2004-12-27
JPH10150994A (ja) 1998-06-09
DK0667901T4 (da) 2008-11-10
FI941837A0 (fi) 1994-04-20
FI981765L (fi) 1998-08-17
WO1993008207A1 (en) 1993-04-29
JP2877788B2 (ja) 1999-03-31
ES2227513T3 (es) 2005-04-01
FI116828B (fi) 2006-03-15
DK0667901T3 (da) 2004-12-27
ATE274055T1 (de) 2004-09-15
ATE239790T1 (de) 2003-05-15
EP0667901A4 (en) 1995-06-22
NO980030L (no) 1998-01-05
JP3308534B2 (ja) 2002-07-29
EP0667901A1 (en) 1995-08-23
CA2312667C (en) 2002-11-19
EP0667901B2 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
DE69233051T2 (de) Antikörper gegen CD40-L
DE69932832T2 (de) Antagonisten auf rezeptorgrundlage und verfahren zu deren herstellung und verwendung
DE69334070T2 (de) Neue zytokine die cd30 binden
DE69633617T2 (de) Il-17 receptor
DE69433552T2 (de) An den zelloberflächenrezeptor hek bindendes cytokin
DE69631331T2 (de) Cd40l mutein
DE69534962T3 (de) Htk-ligand
DE69334111T2 (de) Cd27 ligand
DE69129990T2 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
DE69132306T2 (de) Menschlicher und Murin-Interleukin-5-Rezeptor
DE69132925T2 (de) An stabile proteinkernstruktur gebundene proteinpolyliganden
DE69028671T3 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
DE69334100T2 (de) Elk ligand, ein cytokin
DE68928043T2 (de) Interleukin-4-Rezeptoren
DE69533923T2 (de) Cytokinin-designiertes lerk-5
DE69132937T2 (de) Typ-II-Interleukin-1-Rezeptoren
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
DE69737978T2 (de) Als 2f1 bezeichnetes rezeptorprotein
DE69534235T2 (de) Cytokin lerk-7
DE69332981T2 (de) Methoden zur herstellung löslicher, oligomerer proteine
DE69029545T2 (de) Menschliches GP130-Protein codierende DNS
DE69535719T2 (de) Fas-antigenbindender ligand
DE3851035T2 (de) Interleukin-7.
DD297188A5 (de) Gm-csf und il-3 umfassende fusionsproteine
DE69529822T2 (de) Interleukin-15-rezeptoren

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation